Evidence-based systematic review of Saw palmetto by the Natural Standard Research Collaboration

Journal of the Society for Integrative Oncology

Volumn 4, Issue 4, 2006, Pages 170-186

  Ulbricht, Catherine ^a,l   Basch, Ethan ^b   Bent, Steve ^c   Boon, Heather ^d   Corrado, Michelle ^e   Foppa, Ivo ^f   Hashmi, Sadaf ^g   Hammerness, Paul ^a   Kingsbury, Eileen ^h   Smith, Michael ⁱ   Szapary, Philippe ^j   Vora, Mamta ^k   Weissner, Wendy ^l  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^f UNIVERSITY OF SOUTH CAROLINA   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h UNIVERSITY OF RHODE ISLAND   (United States)

ⁱ CANADIAN COLLEGE OF NATUROPATHIC MEDICINE   (Canada)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k NORTHEASTERN UNIVERSITY   (United States)

^l Natural Standard   (United States)

more..

Author keywords

American dwarf palm tree; Arecaceae (family); Cabbage palm; Dwarf palm; Elusan prostate; IDS 89; LSESR; PA 109; Palmae (family); Palmetto scrub; Palmier de l'amerique du nord; Palmier nain; Permixon; Prostagutt; Prostaserine; Sabal; Sabal serrulata

Indexed keywords

ALFUZOSIN; ANDROID; BICALUTAMIDE; DECADUBROLIN; FINASTERIDE; FLUOXYMESTERONE; FLUTAMIDE; GOSERELIN; HISTRELIN; LEUPRORELIN; METHYLTESTOSTERONE; NANDROLONE DECANOATE; NILUTAMIDE; PLACEBO; PROSTAGUTT; PROSTATA; PYGEUM AFRICANUM EXTRACT; REMIGERON; SABAL EXTRACT; SITOSTEROL; STANOZOLOL; TESTOSTERONE; URTICA EXTRACT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ALLERGY; CARDIOVASCULAR DISEASE; CHOLESTATIC HEPATITIS; CHRONIC PROSTATITIS; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DUODENUM ULCER; EVIDENCE BASED MEDICINE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HALITOSIS; HUMAN; HYPERSENSITIVITY; MALE TYPE ALOPECIA; MENTAL DISEASE; NAUSEA; NEUROGENIC BLADDER; PELVIS PAIN SYNDROME; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; SABAL; STOMACH PAIN; UROGENITAL TRACT DISEASE; VOMITING;

ANDROGEN ANTAGONISTS; ANIMALS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; SERENOA;

EID: 33845234586     PISSN: 1715894X     EISSN: None     Source Type: Journal    
DOI: 10.2310/7200.2006.016     Document Type: Review

References (100)

1. Wilt TJ, Ishani A, Stark G, et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998;280:1604-9.
2. Wilt T, Ishani A, Stark G, et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2000;2:CD001423.
3. Boyle P, Robertson C, Lowe F, Roehrborn C. Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000;55:533-9.
4. Grasso M, Montesano A, Buonaguidi A, et al. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol 1995;48(1):97-103.
5. Oberpichler-Schwenk H. [Finasteride or sabal extract in acne? ] Med Monatsschr Pharm 1998;21(3):83.
6. Grant K. Top-selling herbal supplements. J Managed Primary Care 1999;5:357-70.
7. el Sheikh MM, Dakkak MR, Saddique A. The effect of Permixon on androgen receptors. Acta Obstet Gynecol Scand 1988;67:397-9.
8. 1-adrenoceptor subtypes in vivo? Prostate 2001;46:226-32.
9. Gutierrez M, Garcia de Boto MJ, Cantabrana B, Hidalgo A. Mechanisms involved in the spasmolytic effect of extracts from Sabal serrulata fruit on smooth muscle. Gen Pharmacol 1996;27(1):171-6.
10. Lowe FC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia: an update. Urology 1999;53:671-8.
11. Bach D, Ebeling L. Long-term drug treatment of benign prostatic hyperplasia - results of a prospective 3-year multicenter study using Sabal extract IDS 89. Phytomed 1996;3:105-11.
12. Anonymous. Effectiveness of lipidosterol extract Serenoa repens (Permixon) in patients with prostatic hyperplasia. Urologiia 2002;1:23-5.
13. Stepanov VN, Siniakova LA, Sarrazin B, Raynaud JP. Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens. Adv Ther 1999;16:231-41.
14. Cheema P, El Mefty O, Jazieh AR. Intraoperative haemorrhage associated with the use of extract of saw palmetto herb: a case report and review of literature. J Intern Med 2001;250:167-9.
15. Feifer AH, Fleshner NE, Klotz L. Analytical accuracy and reliability of commonly used nutritional supplements in prostate disease. J Urol 2002;168(1):150-4.
16. Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health Syst Pharm 1999;56:125-38.
17. Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006;354:557-66.
18. Braeckman J, Bruhwyler J, Vandekerckhove K, et al. Efficacy and safety of the extract of Serenoa repens in the treatment of benign prostatic hyperplasia: therapeutic equivalence between twice and once daily dosage forms. Phytother Res 1997;11:558-63.
19. Roveda S, Colombo P. Clinical controlled trial on therapeutical bioequivalence and tolerability of Serenoa repens oral capsules 160mg or rectal capsules 640mg. Arch Med Interna 1994;46(2):61-75.
20. Marks LS, Tyler VE. Saw palmetto extract: newest (and oldest) treatment alternative for men with symptomatic benign prostatic hyperplasia. Urology 1999;53:457-61.
21. Ondrizek RR, Chan PJ, Patton WC, King A. An alternative medicine study of herbal effects on the penetration of zona-free hamster oocytes and the integrity of sperm deoxyribonucleic acid. Fertil Steril 1999;71:517-22.
22. Small EJ, Frohlich MW, Bok R, et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 2000;18:3595-603.
23. Braeckman J. The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Curr Ther Res 1994;55:776-85.
24. Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996;29:231-40.
25. Braeckman J, Denis L, de Leval J, et al. A double-blind, placebo-controlled study of the plant extract Serenoa repens in the treatment of benign hyperplasia of the prostate. Eur J Clin Res 1997;9:247-59.
26. Reece-Smith H, Memon A, Smart C, et al. The value of Permixon in benign prostatic hypertrophy. Br J Urol 1986;58(1):36-40.
27. Marks LS, Partin AW, Epstein JI, et al. B. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000;163:1451-6.
28. Di Silverio F, D'Eramo G, Lubrano C, et al. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol 1992;21:309-14.
29. Elghamry MI, Hansel R. Activity and isolated phytoestrogen of shrub palmetto fruits (Serenoa repens Small), a new estrogenic plant. Experientia 1969;25:828-9.
30. DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998;339:785-91.
31. Gerber GS, Kuznetsov D, Johnson BC, Burstein JD. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 2001;58:960-4.
32. Hamid S, Rojter S, Vierling J. Protracted cholestatic hepatitis after the use of prostata. Ann Intern Med 1997;127:169-70.
33. Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 1984;18:461-2.
34. Kaplan SA, Volpe MA, Te AE. A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. J Urol 2004;171(1):284-8.
35. Gerber GS, Zagaja GP, Bales GT, et al. Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology 1998;51:1003-7.
36. Descotes J, Rambeaud J, Deschaseaux P, et al. Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 1995;9:291-7.
37. Marks LS, Hess DL, Dorey FJ, et al. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology 2001;57:999-1005.
38. Strauch G, Perles P, Vergult G, et al. Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol 1994;26:247-52.
39. 1-adrenoceptors in vitro. Prostate 1999;38:208-15.
40. Briley M, Carilla E, Fauran F. Permixon, a new treatment for benign prostatic hyperplasia, acts directly at the cytosolic androgen receptor in the rat prostate. Br J Pharmacol 1983;79:327P.
41. Ravenna L, Di Silverio F, Russo MA, et al. Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines. Prostate 1996;29:219-30.
42. Stenger A, Rarayre JP, Carilla E. Etude pharmacologizue et biochimique de l'extrait hexanique de Serenoa repens B. Gaz Med Fr 1982;89:2041-8.
43. Rhodes L, Primka RL, Berman C, et al. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate 1993;22(1):43-51.
44. Hiermann A. [The contents of sabal fruits and testing of their anti-inflammatory effect.] Arch Pharm (Weinheim), 1989;322:111-4.
45. Breu W, Hagenlocher M, Redl K, et al. [Anti-inflammatory activity of Sabal fruit extracts prepared with supercritical carbon dioxide. In vitro antagonists of cyclooxygenase and 5-lipoxygenase metabolism.] Arzneimittelforschung 1992;42:547-51.
46. Paubert-Braquet M, Mencia Huerta JM, Cousse H, Braquet P. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids 1997;57:299-304.
47. Mitropoulos D, Kiroudi A, Mitsogiannis I, et al. In vivo effect of the lipido-sterolic extract of Serenoa repens (Permixon) on mast cells accumulation and glandular epithelium trophism in the rat prostate. J Urol 1999;161(4S):362.
48. Bayne CW, Ross M, Donnelly F, Habib FK. The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate. J Urol 2000;164(3 Pt 1):876-81.
49. Paubert-Braquet M, Richardson FO, Servent-Saez N, et al. Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat. Pharmacol Res 1996;34:171-9.
50. Paubert-Braquet M, Raynaud JP, Braquet PG, et al. Permixon [lipid sterolic extract of Serenoa repens (LSESr)] and some of its components inhibits b-FGF and EGF induced proliferation of human prostate organotypic cell lines. J Urol [Suppl] 1997;157:138.
51. Paubert-Braquet M, Cousse H, Raynaud JP, et al. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol 1998;33:340-7.
52. Vacherot F, Azzouz M, Gil-Diez-De-Medina S, et al. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSEr, Permixon) in benign prostatic hyperplasia. Prostate 2000;45:259-66.
53. Van Coppenolle F, Le Bourhis X, Carpentier F, et al. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride. Prostate 2000;43(1):49-58.
54. Ishii K, Usui S, Sugimura Y, et al. Extract from Serenoa repens suppresses the invasion activity of human urological cancer cells by inhibiting urokinase-type plasminogen activator. Biol Pharm Bull 2001;24:188-90.
55. Iguchi K, Okumura N, Usui S, et al. Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells. Prostate 2001;47(1):59-65.
56. Bayne C, Donnelly F, Ross M, et al. Serenoa repens (Permixon): a 5 alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate 1999;40:232-41.
57. Iehle C, Delos S, Guirou O, et al. Human prostatic steroid 5 alpha-reductase isoforms - a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995;54:273-9.
58. Weisser H, Tunn S, Behnke B, Krieg M. Effects of the Sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. Prostate 1996;28:300-6.
59. Buck AC. Phytotherapy for the prostate. Br J Urol 1996;78:325-36.
60. Di Silverio F, Monti S, Sciarra A, et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998;37(2):77-83.
61. Epstein J, Partin A, Simon I, et al. Prostate tissue effects of saw palmetto extract in men with symptomatic BPH. J Urol 1999;161(4S):362.
62. Casarosa C, Cosci di Coscio M, Fratta M. Lack of effects of a lyposterolic extract of Serenoa repens on plasma levels of testosterone, follicle-stimulating hormone, and luteinizing hormone. Clin Ther 1988;10:585-8.
63. Plosker GL, Brogden RN. Serenoa repens (Permixon): a review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996;9:379-95.
64. De Bernardi VM, Tripodi AS, Contos S, et al. Serenoa repens capsules: a bioequivalence study. Acta Toxicol Ther 1994;15(1):21-39.
65. Markowitz JS, Donovan JL, Devane CL, et al. Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin Pharmacol Ther 2003;74:536-42.
66. Boccafoschi C, Annoscia S. Confronto fra estratto di Serenoa repens e placebo mediante prova clinica controllata in pazienti con adenomatosi prostatica. Urologia 1983;50:1257-68.
67. Carbin BE, Larsson B, Lindahl O. Treatment of benign prostatic hyperplasia with phytosterols. Br J Urol 1990;66:639-41.
68. Champault G, Bonnard AM, Cauquil J, Patel JC. [Medical treatment of prostatic adenoma. Controlled trial: PA 109 vs placebo in 110 patients.] Ann Urol (Paris) 1984;18:407-10.
69. Cukier J, Ducassou J, Le Guillou M, et al. Permixon versus placebo; resultats d'une etude multicentrique. C R Ther Pharmacol Clin 1985;4(25):15-21.
70. Emili E, Lo Cigno M, Petrone U. Risultati clinici su un nuovo farmaco nella terapia dell'ipertrofia della prostata (Permixon). Urologia 1983;50:1042-8.
71. Gabric V, Miskic H. Behandlung des benignen Prostataadenoms und der chronischen Prostatitis. Placebokontrollierte randomisierte doppelblindstudie mit Prostagutt. Therapiewoche 1987;37:1775-88.
72. Löbelenz J. Extractum Sabal fructus bei benigner Prostatahyperplasie (BPH): Klinische Prüfung im Stadium I und II. Therapeutikon 1992;6(1-2):34,37.
73. Mandressi A, Tarallo U, Maggioni A, et al. Terapia medica dell'adenoma prostatico: confronto della efficacia del'estratto di Serenoa repens (Permixon) versus l'estratto di pigeum africanum e placebo. Valutazione in doppio cieco. Urologia 1983;50:752-7.
74. Mattei FM, Capone M, Acconcia A. Medikamentose therapie der benignen prostatahyperplasie mit einem extrakt der sagepalme. TW Urol Nephrol 1990;2:346-50.
75. Metzker H, Kieser M, Hölscher U. Wirksamkeit eines Sabal-Urtica-kombinationspraparates bei der behandlung der benignen prostatahyperplasie (BPH). Urologe 1996;36:292-300.
76. Pannunzio E, D'Ascenzo R, Giardinetti F, et al. Serenoa repens vs. gestonorone caproato nel trattamento dell'ipertrofia prostatica benigna. Studio randomizzato. Urologia 1986;53:696-705.
77. Sökeland J, Albrecht J. Kombination aus Sabal und Urticaextrakt vs. finasterid bei BPH (Stad I bis II nach Alken). Urologe 1997;36:327-33.
78. Tasca A, Barulli M, Cavazzana A, et al. [Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens. Double-blind clinical study vs. placebo.] Minerva Urol Nefrol 1985;37(1):87-91.
79. Semino A, Ortega L, Cobo G, et al. [Symptomatic treatment of benign hypertrophy of the prostate. Comparative study of prazosin and Serenoa repens.] Archivos Espanoles de Urologia 1992;45:211-3.
80. Authie D, Cauquil J. Appreciation de l'efficacite de permixon en pratique quotidienne. [Appreciation of the in practice daily effectiveness of Permixon.] C R Ther Pharmacol Clin 1987;5(56):4-13.
81. Bauer HW, Casarosa C, Cosci M, et al. [Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study.] MMW Fortschr Med 1999;141(25):62.
82. Foroutan F. Wirksamkeit und vertraglichkeit von permixon bei einem grosseren patientenkollektiv (592 patienten) unter praxisbedingungen. J Urol Urogynakol 1997;2:17-21.
83. Willetts KE, Clements MS, Champion S, et al. Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. BJU Int 2003;92:267-70.
84. Mohanty NK, Jha RJ, Dutt C. Randomized double-blind controlled clinical trial of Serenoa repens versus placebo in the management of patients with symptomatic grade I to grade II benign prostatic hyperplasia (BPH). Indian J Urol 1999;16(1):26-31.
85. Comar OB, Di Rienzo A. Mepartricina versus Serenoa repens: studio sperimentale doppio cieco su 20 casi di iperplasia prostatica benigna. Riv Ital Biol Med 1986;6:122-5.
86. Flamm J, Kiesswetter H, Englisch M. [An urodynamic study of patients with benign prostatic hypertrophy treated conservatively with phytotherapy or testosterone (author's translation).] Wien Klin Wochenschr, 1979;91:622-7.
87. Romics I, Schmitz H, Frang D. Experience in treating benign prostatic hypertrophy with Sabal serrulata for one year. Int Urol Nephrol 1993;25:565-9.
88. Schneider HJ, Honold E, Masuhr T. [Treatment of benign prostatic hyperplasia. Results of a treatment study with the phytogenic combination of Sabal extract WS 1473 and Urtica extract WS 1031 in urologic specialty practices.] Fortschr Med 1995;113(3):37-40.
89. Vahlensieck W Jr, Volp A, Lubos W, Kuntze M. [Benign prostatic hyperplasia - treatment with Sabal fruit extract. A treatment study of 1,334 patients.] Fortschr Med 1993;111:323-6.
90. Medvedev AA, Siniakova LA, Zaitsev AV. [Prostaplant treatment of benign prostatic hyperplasia.] Urologia, 2000;4:13-5.
91. Tosto A, Rovereto B, Paoletti MC, et al. Study of Serenoa repens in treatment of functional secondary adenoma of the prostate: consideration of 20 cases. Urologia 1985;52:536-42.
92. Greca P, Volip R. Experience with a new drug in the medical treatment of prostatic adenoma. Urologia 1985;52:532-5.
93. Carreras JO. Novel treatment with a hexane extract of Serenoa repens in the treatment of benign prostatic hypertrophy. Archiv Esp de Urolog 1987;40:310-3.
94. Redecker KD. [Sabal extract WS 1473 in benign prostatic hyperplasia.] Extracta Urologica, 1998;21(3):23-5.
95. Ziegler H, Holscher U. Efficacy of saw palmetto fruit special extract WS1473 in patients with Alken stage I-II benign prostatic hyperplasia - open multicentre study. Jatros Uro 1998;14(3):34-3.
96. Paoletti PP, Francalanci R, Tenti S, et al. Medical treatment of prostatic hypertrophy. Experience with Serenoa repens extract. Urologia 1986;53:182-7.
97. Kondas J, Philipp V, Dioszeghy G. Sabal serrulata extract (Strogen forte) in the treatment of symptomatic benign prostatic hyperplasia. Int Urol Nephrol 1996;28:767-72.
98. Cirillo-Marucco E, Pagliarulo A, Tritto G, et al. L'estratto di Serenoa repens (Permixon) nel trattamento precoce dell'ipertrofia prostatica . Urologia 1983;50:1269-77.
99. Morganti P, Fabrizi G, James B, et al. Effect of gelatin-cystine and Serenoa repens extract on free radicals level and hair growth. J Appl Cosmetol 1998;16:57-64.
100. Timmermans LM, Timmermans LG, Jr. [Determination of the activity of extracts of Echinaceae and Sabal in the treatment of idiopathic megabladder in women.] Acta Urol Belg, 1990;58(2):43-59.